FDC Limited (NSE:FDC)
India
· Delayed Price · Currency is INR 461.50
+0.90 (0.20%)
Feb 11, 2025, 3:30 PM IST
FDC Limited Revenue
FDC Limited had revenue of 5.14B INR in the quarter ending September 30, 2024, with 5.65% growth. This brings the company's revenue in the last twelve months to 20.72B, up 11.01% year-over-year. In the fiscal year ending March 31, 2024, FDC Limited had annual revenue of 19.43B with 8.92% growth.
Revenue (ttm)
20.72B
Revenue Growth
+11.01%
P/S Ratio
n/a
Revenue / Employee
3.11M
Employees
6,659
Market Cap
71.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 19.43B | 1.59B | 8.92% |
| Mar 31, 2023 | 17.84B | 2.56B | 16.74% |
| Mar 31, 2022 | 15.28B | 1.95B | 14.61% |
| Mar 31, 2021 | 13.33B | -109.88M | -0.82% |
| Mar 31, 2020 | 13.44B | 2.53B | 23.24% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 204.69B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
FDC Limited News
- 2 months ago - FDC receives US FDA approval for Cefixime 400 mg tablets - Business Upturn
- 5 months ago - FDC shares surge 11%, leading gains in BSE Healthcare index - Business Upturn